European AIDS Treatment Group

EU Civil Society Forum (CSF) on HIV , TB and Hepatitis ;
EU Civil Society Forum on Drugs
WHO Regional Coordination Committee on HIV, TB and Hep
AIDS Action Europe;
European Public Health Alliance (EPHA);
European Forum for Good Clinical Practice (EFGCP)
European Patient Forum (EPF)
Platform for Cooperation with undocumented migrants (PICUM)
ILGA – Europe
International Committee on Rights of Sex Workers (ICRSE)

None declared

Jan 2019 - Dec 2019

37,500€

233,563 € (Source: H2020 IMI)

None declared

Commission expert group - Civil Society Forum on Drugs#E02681#http://ec.europa.eu/transparency/regexpert/index.cfm?do=groupDetail.groupDetail&groupID=2681 #Member #C#Civil society#Sub-group on Relations with International Institutions

N/A

EU Civil Society forum on HIV, TB and Hepatitis relaunch and secretariat with AAE, EHRA, Correlations, TBEC.
The EMERGE project (Evaluating mHealth technology in HIV to improve Empowerment and healthcare utilisation: Research and innovation to Generate Evidence for personalised care) is a mHealth platform to enable self-management of HIV in patients with stable disease. TheEATG produced a brief on overcoming barriers to the implementation m-health solutions. On 2 September 2020, a multi-stakeholder meeting on the future of M-health in Europe was organised, drawing on the EmERGE project findings. The meeting also included a discussion on the EmERGE, mHealth and health systems in the EU and essons from the COVID-19 Crisis and the role of digital pathways in HIV prevention and care. platform will provide users with web based and mobile device applications which interface securely with relevant medical data and facilitate remote access to key healthcare providers. EATG was a will be acting as community partner, supporting standards for HIV care and guidelines for routine monitoring both in the involved countries and more broadly across the EU and potentially wider.
ESTICOM – EUROPEAN SURVEYS AND TRAININGS TO IMPROVE MSM COMMUNITY HEALTH aims to strengthen the community response and raise awareness about the persisting legal, structural, political and social barriers hindering a more effective response to the syndemics of HIV, hepatitis viruses B and C, and other STI among MSM. The main activities include surveys among MSM (EMIS2017) and Community Based Health Workers (ECHOES) as well as a training programme for Community Health Workers intended to be adaptable for all EU countries.
HIVACAR – EVALUATING A COMBINATION OF IMMUNE-BASED THERAPIES TO ACHIEVE A FUNCTIONAL CURE OF HIV INFECTION. The project aims to change the current paradigm of HIV treatment by obtaining a functional cure for HIV thanks to effectively targeting residual virus replication and viral reservoirs.
EHVA – EUROPEAN HIV VACCINE ALLIANCE, AN EU PLATFORM FOR THE DISCOVERY AND EVALUATION OF NOVEL PROPHYLACTIC AND THERAPEUTIC VACCINE CANDIDATES. Project aims: To develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The MVP includes four components: 1) Discovery, 2) Immune Profiling, 3) Data Management, Integration and Down-Selection, and 4) Clinical Trials.
EFOEUPATI - Ensuring the future of EUPATI beyond 2020 aims to ensure the sustainability of the results of the EUPATI project, to develop sustainable models of collaboration to ensure this, and put into place the infrastructure required for these to work, building on those already established under IMI-EUPATI.
PARADIGM - Patients Active in Research and Dialogues for an Improved Generation of Medicines – This IMI project aims to provide a framework that allows structured, meaningful, sustainable and ethical patient engagement throughout three key decision-making points of the development of medicinal products: (i) the research priority setting; (ii) the design of clinical trials and (iii) the early dialogues with regulators and HTA bodies. The work builds upon previous initiatives such the European Patients’ Academy (EUPATI) and Patient Focused Medicine Development (PFMD).

Achievements:
EATG has been at the forefront of community involvement in treatment development in HIV and co-infections. Our models of community involvement are shared with patient organisations beyond the HIV and co-infections field. EATG has been leading on innovative techniques such as biomedical prevention and HIV cure research.
EATG has been actively involved in setting up the EU Civil Society Forum on HIV, hepatitis and TB. Currently we are playing a leading role in the reform of the CSF.
In 1997 EATG created the European Community Advisory Board (ECAB) to address key science and policy issues related to HIV and its main co-infections like hepatitis C or tuberculosis. Today and in the coming years, these ECABs will remain one of EATG’s core activities. This model of high-level scientific platform has been copied by other national and international community groups and networks (e.g. Portuguese CAB, EECA CAB, TB CAB, Positive Council Switzerland etc.)
Via our ‘Sitges’ meetings, EATG has driven the community input in HCV cure development.
EATG provides capacity building to different stakeholders, thus supporting better networking (especially in Central and Eastern Europe), increased capacity of PLHIV and health care providers, but also – via follow up activities – direct involvement of these people in new scientific and policy activities.
Population(s) served:
The European AIDS Treatment Group (EATG) is a patient-led NGO that advocates for the rights and interests of people living with or affected by HIV/ AIDS and related co-infections within the WHO Europe region. It is a network of more than 170 nationally based members from 47 countries in Europe. Our members are PLHIV and representatives of different communities affected by HIV/AIDS and co-infections. EATG represents the diversity of more than 2.3 million people living with HIV (PLHIV) in Europe as well as those affected by HIV/AIDS and co-infections.
Our members are representatives of different communities affected by HIV/AIDS in Europe. Our members are expert patients and treatment advocates coming from the WHO European region continuously working together to end the epidemic by advancing research on HIV/AIDS, broadening access to treatment, training/mentoring new HIV/AIDS advocates and ensuring that the patient Community is a permanent and highly-recognised voice in the research arena.
EATG has close links with groups and organisations within the area of sex work, drug use, MSM, migrants, prisoners etc.. Our work is also in close collaboration with organisations that work on related topics such as vaccine development, prevention, liver disease, sexual health or human rights issues such as stigma and discrimination.
Involvement of PLWH:
EATG is a membership driven organisation. Our members are all members of the General Assembly (GA), the highest decision-making body of the EATG. A major part of our members are PLHIV. The GA is called at least annually by the Board of Directors (BoD). The GA elects the members of the BoD and other bodies. Directors are elected for a period of two years.
HIV positive members are also represented within each part of the structure (selected via democratic systems): Programme Chairs; BoD members, staff and other internal positions. EATG has 3 Programme Areas: Quality of Life, Combination Prevention and Partners in Science. Members become active within one or more of the Programmes, as part of designated Programme Committees or ad hoc task groups. EATG regularly organises consultations with its members and other groups. We actively support the GIPA principle.
Members are the main drivers of our strategic development. With support from the office members, they draft our long-term strategy, set priorities etc. We have many HIV-positive members involved as representatives within different structures and positions such as steering committees, scientific committees, and advisory boards.

2 meetings found. Download meetings

The list below only covers meetings held since November 2014 with commissioners, their cabinet members or directors-general at the European Commission; other lobby meetings with lower-level staff may have taken place, but the European Commission doesn't proactively publish information about these meetings. For more information about which commissioner is responsible for which portfolio, check out this link: https://commissioners.ec.europa.eu/index_en All information below comes from European Commission web pages.

• Date	22 Jul 2019	Location	Brussels
  Subject	Access to medicines
  Cabinet	Cabinet of Commissioner Vytenis Andriukaitis
  Portfolio	Health & Food Safety
  Attending	Arunas Vinciunas (Cabinet member) Vytenis Andriukaitis (Commissioner) Alina Timofte (Cabinet member)
  Other Lobbyists	The European Association of Hospital Pharmacists Association Belge des Consommateurs Test-Achats / Belgische Verbruikersunie Test-Aankoop

• Date	28 Nov 2016	Location	Brussels
  Subject	EU and NGOs action on HIV, TB and Hepatitis
  Cabinet	Cabinet of Commissioner Vytenis Andriukaitis
  Portfolio	Health & Food Safety
  Attending	Paula Duarte Gaspar (Cabinet member) Vytenis Andriukaitis (Commissioner)
  Other Lobbyists	European Liver Patients' Association Deutsche Aidshilfe GLOBAL HEALTH ADVOCATES